NKGN (NKGen Biotech) Other Long Term Assets : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Other Long Term Assets?

NKGen Biotech's other long-term assets for the quarter that ended in Sep. 2024 was $0.00 Mil.

NKGen Biotech's annual other long-term assets declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

NKGen Biotech Other Long Term Assets Historical Data

The historical data trend for NKGen Biotech's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Other Long Term Assets Chart

NKGen Biotech Annual Data

Trend

Dec21

Dec22

Dec23

Other Long Term Assets

NKGen Biotech Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Long Term Assets	Get a 7-Day Free Trial					-	-	-	-	-

NKGen Biotech Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

NKGen Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (OTCPK:NKGN) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

3001 Daimler Street, Santa Ana, CA, USA, 92705

Website

https://www.nkgenbiotech.com

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.